Also it should be mentioned that the ovarian cancer study used treatment-naive subjects just diagnosed with ovarian cancer, and this study used advanced SS subjects on a range of salvage therapies some of which might work to decrease in vivo Tregs cell numbers thus accounting for the more dramatic Tregs effect of TNFR2 antagonism. The gene discussed is TNFRSF1B; the disease is synovial sarcoma.